US 10308646
Pyrimidine compound as JAK kinase inhibitor
granted A61KA61K31/506A61K45/06
Quick answer
US patent 10308646 (Pyrimidine compound as JAK kinase inhibitor) held by Theravance Biopharma R&D IP, LLC expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 32
- CPC classes
- A61K, A61K31/506, A61K45/06, A61K9/0014, A61K9/06